Introduction
By the time most patients with pancreatic cancer develop symptoms, they already have advanced stage disease and are no longer candidates for surgery (1) . These patients have a >95% 3-year mortality rate (2) . By contrast, patients with small lymph-node negative pancreatic carcinomas have 5-year survival rates approaching 40% following surgical resection of their neoplasms (3) . Clearly, we need to improve our understanding of early pancreatic neoplasms, so that new techniques can be developed to detect these neoplasms early while they are still surgically treatable.
Morphologic studies
The histologic examination of pancreatic parenchyma adjacent to infiltrating pancreatic carcinomas was the first step in the identification of the precursors to infiltrating carcinomas of the pancreas. In 1976, Cubilla and Fitzgerald published a landmark paper in which they reported that papillary epithelial proliferations in pancreatic ducts are more common in pancreata with infiltrating carcinoma than they are in pancreata without cancer (4) . Furthermore, papillary duct lesions with atypia were seen only in pancreata with infiltrating carcinomas (4). In 1979, Kozuka et al extended these observations by Fitzgerald and Cubilla and reported that, like infiltrating adenocarcinoma of the pancreas, pancreatic duct lesions are extremely rare in children, increase with advancing age, and are more common in the. head of the pancreas then they are in the body or tail of the gland (5). These similarities in anatomic distribution and age of onset suggest a relationship between pancreatic duct lesions and invasive carcinomas; however, they do not establish a precursor role for duct lesions (6) . In order to demonstrate that duct lesions are the precursors lo infiltrating carcinoma, one needs to examine serial samples taken over time. This has recently been accomplished by Brat et al (7) . Brat et al reported 3 patients from Johns Hopkins who had a portion of their pancreas resected. Histologic examination of the resected portion of the pancreas from these patients revealed duct lesions and these 3 patients were remarkable because they later developed an infiltrating adenocarcinoma of the pancreas (7). Therefore, not only is there an anatomic association between pancreatic duct lesions and infiltrating cancers, but duct lesions have also been documented in pancreata which later developed an infiltrating carcinoma. These observations strongly support a precursor role for duct lesions in the development of infiltrating adenocarcinoma of the pancreas.
Histologic classification of duct lesions
The next step in the evaluation of duct lesions is to define the molecular genetic alterations present in these lesions. Before this can be accomplished, however, we need a standard terminology and uniform classification scheme for these duct lesions. We have therefore suggested the classification scheme illustrated in Figure 1 . "Flat duct lesions" are epithelial proliferation composed of a single layer of columnar cells without significant nuclear atypia ( Figure 1A ). "Papillary duct lesions without atypia" are papillary proliferations in which the epithelial cells lack significant cytologic and architectural atypia ( Figure IB) . "Atypical papillary duct lesions" are characterized by a papillary architecture and epithelial cells with nuclear atypia, including prominent nucleoli and occasional mitoses ( Figure  1C ). "Carcinoma in situ" are markedly atypical papillary proliferations which lack fibrovascular stalks and which contain significant nuclear and cytologic atypia, including epithelial bridge formation, multiple nucleoli, and atypical mitoses ( Figure ID) . While it is recognized that duct lesions in fact form a continuum, this classification scheme does provide a set of standards which can be referred to when defining the molecular alterations present in a given lesion.
Genetic changes in early pancreatic neoplasia
Duct lesions have been shown to harbor a number of genetic changes, and many of these genetic changes are similar to those seen in infiltrating adenocarcinomas of the pancreas. These include activation of K-ras and inactivation of the pl6, p53, and BRCA2 tumor-suppressor genes.
K-ras
Activating point mutations in codon 12 in the K-ras oncogene are one of the most common genetic alterations in infiltrating adenocarcinomas of the pancreas (8) (9) (10) (11) (12) (13) (14) . It is therefore not surprising that K-ras mutations were among one of the first genetic alterations identified in early duct lesions in the pancreas (15) (16) (17) (18) (19) (20) (21) (22) (23) . In general, histologically normal ductal epithelial cells lack K-ras mutations, and the prevalence of these mutations increases as one moves from flat duct lesions, to papillary duct lesions without atypia, to papillary duct lesions with atypia, to carcinoma in situ (21) .
p!6
The pl6 tumor-suppressor gene is inactivated in >95% of infiltrating adenocarcinomas of the pancreas (24-31), and Moskaluk et al have recently demonstrated that pl6 is also inactivated in some duct lesions (21). Moskaluk et al analyzed duct lesions adjacent to four infiltrating adenocarcinomas which harbored pl6 mutations. They found that 3 of the 9 duct lesions adjacent to these carcinomas harbored pi6 alterations (21) . In two patients the pi 6 mutations identified in the infiltrating carcinoma and in the duct lesions were the same, but in one patient two separate duct lesions were identified, each of which harbored a different pi6 mutation (21) . These findings suggest a field effect in which multiple duct lesions develop in the pancreas. Some progress to infiltrating carcinomas while others do not (32) .
p53
The/753 tumor-suppressor gene is inactivated in 50-70% of infiltrating adenocarcinomas of the pancreas (33) (34) (35) (36) (37) (38) (39) (40) . Although an imperfect surrogate for sequencing, immunohistochemical staining for the p53 gene product has been used to analyze duct lesions forp53 alterations (34, 41) . The expression of the p53 gene product to immunohistochernically detectable levels suggest a p53 mutation, while failure of a cell to label with antibodies to p53 suggests wild-type p53. This is because mutated p53 is more stable than its wild-type counterpart. DiGiuseppe et al labeled a large series of pancreatic carcinomas using antip53 antibodies and demonstrated immunohistochemically detectable levels of p53 in in situ carcinomas (34) . These observations, and similar ones made by Hameed et al, suggests that p53 is inactivated in duct lesions with significant cytological and architectural atypia (34, 41) .
BRCA2
Although BRCA2 is only rarely inactivated in infiltrating adenocarcinoma of the pancreas, approximately 7% of patients with pancreatic carcinomas harbor germline BRCA2 mutations (42, 43) . These patients provide a unique opportunity to study duct lesions for inactivation of BRCA2. Goggins et al microdissected pancreata resected from 3 patients with germline BRCA2 mutations (44) . The second allele of BRCA2 was intact in all 12 papillary duct lesions without atypia and in the two flat duct lesions examined, while the single papillary duct lesion with atypia included in the series demonstrated loss of the wild-type BRCA2 allele (44) . BRCA2 function would therefore have been lost in this atypical papillary duct lesion. These findings suggest that inactivation of BRCA2 is a rare and relatively late event in the development of pancreatic neoplasia. 
Discussion
Morphologic and molecular analyses have demonstrated that duct lesions are the precursors to infiltrating carcinoma of the pancreas. We believe that there is a progression from normal duct epithelium, to flat duct lesions, to papillary duct lesions without atypia, to papillary duct lesions with atypia, to carcinoma in situ, to infiltrating carcinoma. This progression is associated with the accumulation of mutations in a variety of cancer-causing genes, including K-ras, p53, pl6, and BRCA2. Duct lesions are therefore best considered true neoplasms and not reactive processes. Furthermore, because these genetic alterations occur while the neoplasm is still in situ, before it has spread beyond the pancreas, genetic alterations may form the foundation for new screening tests to detect early pancreatic neoplasms.
